

Zyprexa Publications to 2000

1. Published in 2000

1.1. Published in 2000: MEDICAL MANUSCRIPTS

1. Braus DF, Schmitt A, Czekalla J, Severa L. Therapy-resistant psychotic-depressive disorder. Remission with a selective serotonin reuptake inhibitor in combination with olanzapine. *Clinical Drug Investigation* 2000; 20(6): 455-459. Dec. [Case Report]
2. Breier A. The effects of olanzapine on cognition. *CNS Drug Reviews* 2000; 6(suppl 1):35
3. Bymaster FP, Falcone JF. Decreased binding affinity of olanzapine and clozapine for clonal human muscarinic receptor subtypes in intact CHO cells in physiological medium. *European Journal of Pharmacology* 2000; 390:245-248. Mar.
4. Chengappa KNR, Jacobs TG, Sanger TM, Tohen M, Levine J, Thase M, Kupfer DJ. Response to placebo or olanzapine among bipolar I disorder patients experiencing their first manic episode. *Bipolar Disorders* 2000; 2(4):332-335. Dec. [HGEH]
5. David SR, Taylor C, Kinon B, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin concentrations in patients with schizophrenia. *Clinical Therapeutics* 2000; 22(9):1085-1096. Sep. [HGAJ, HGBG, P022]
6. Dittmann RW. Olanzapine in the treatment of children and adolescents with pervasive developmental disorders. *Child and Adolescent Psychopharmacology News* 2000; 5(2):1-4. [Review]
7. Dossenbach MRK, Beuzen J-N, Avnon M, Belmaker RH, Elizur A, Mark M, Munitz H, Schneidman M, Shoshani D, Kratky P, Grundy SL, Tollefson GD. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive or unable to tolerate clozapine. *Clinical Therapeutics* 2000; 22(9):1021-1034. Sep. [HGCM]
8. Gomez JC, Breier A, Hernandez J, Sacristán J, Carrasco PR, Anton C, Fontova Carbonell E, and the EFESO Study Group. The safety of olanzapine compared to other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia. *Journal of Clinical Psychiatry* 2000; 61:335-343. May. [EFESO, HGSJ]
9. Grothe DR, Bergstrom RF, Kurtz DL, Calis KA, Jacobsen L, Kumra S, Lindsay C, Rapoport JL. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood onset schizophrenia. *Journal of Clinical Psychopharmacology* 2000; 20(2):220-225. [Pharmacokinetics]
10. Gury C, Canceil O, Iaria P. Antipsychotiques et sécurité cardiovasculaire: données actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires [Antipsychotics and cardiovascular safety: current data on QT interval lengthening and the risk of ventricular arrhythmia]. *L'Encéphale* 2000; 26:62-72.
11. Ishigooka J, Murasaki M, Miura S, and the Olanzapine Late Phase II Study Group. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. *Psychiatry and Clinical Neurosciences* 2000; 54(4):467-478. Aug.
12. Kennedy JS, Bymaster F, Basson BR, Gilmore JA, Tran PV. The comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone in man. *Primary Care Companion* 2000; 2(4):122-126. [HGBG]
13. Kinon BJ, Basson BR, Malcolm SK, Gilmore JA, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. *Journal of Clinical Psychiatry* 2000; 61(11): 833-840. Nov. [HGFW]
14. Kutner NG, Brown PJ, Stavisky RC, Clark WS, Green RC. "Friendship" interactions and expression of agitation among residents of a dementia care unit. *Research on Aging* 2000; 22(2):188-205. Mar.
15. Patri E, Dantchev N, Martinez M. Prise de poids et traitement antipsychotique [Weight gain and antipsychotic treatment]. *L'Encéphale* 2000; 26: 93-97.
16. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD, for the Canadian Collaborative Group for Research on Cognition in Schizophrenia.

ZY 2230 1862

- Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. *Archives of General Psychiatry* 2000; 57:249-258. Mar. [Po22]
17. Sacchetti E, Guarneri L, Bravi D. H₂ antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients: a case report. *Biological Psychiatry* 2000; 48(2):167-168. Jul 15.
 18. Sacristan J, Gómez JC, Montejo A, Vieta E, Gregor K, and the EFESO Study Group. Doses of olanzapine, risperidone and haloperidol in clinical practice: results of a prospective pharmacoepidemiological study. *Clinical Therapeutics* 2000; 22:583-599. May. [EFESO, HGGS]
 19. Schmitt A, Braus DF. Die effektivere Behandlung einer depressiven Störung mit psychotischen Symptomen durch Kombination mit Olanzapin [Effective treatment with olanzapine of a depressive syndrome with psychotic symptoms]. *Deutsche Medizinische Wochenschrift* 2000; 125(50):1526-1529.
 20. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized trial. *Archives of General Psychiatry* 2000; 57(10):968-976. 14 Oct. [HGEU]
 21. Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, Wei H. Olanzapine for psychotic conditions in the elderly. *Psychiatric Annals* 2000; 30(3):191-196. Mar. [HGAJ, HGEH, HGEU]
 22. Tohen M, Breier A, Feldman PD, Sanger TM. Gender differences in responses to treatment in first-episode psychosis: olanzapine versus haloperidol. *Essential Psychopharmacology* 2000; 3(4):37-50. Dec. [HGAJ]
 23. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. *Bipolar Disorders* 2000; 2(3 Pt 2):261-268. Oct. [HGEH, HGGW, Review]
 24. Tohen M, Jacobs TG, Grundy SL, Banov MC, McElroy SL, Janicak PG, Zhang F, Toma V, Francis J, Sanger T, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. *Archives of General Psychiatry* 2000; 57(9):841-849. Sep. [HGGW]
 25. Tollefson GD, Jones B, Taylor C, Wright P. The pharmacology, efficacy & safety of the novel antipsychotic agent, olanzapine. *Advances in Preclinical and Clinical Psychiatry* 2000; 2:111-122. [Review]
 26. Tollefson GD, Taylor C. Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent [review]. *CNS Drug Reviews* 2000; 6(4):303-362. [E003, HGAD, HGAJ, HGAP, HGBA, HGBG, HGBK, HGCF, HGCH, HGEH, HGEJ, Po22]
 27. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. *Neuropsychopharmacology* 2000; 23(3):250-262. Sep. [Preclinical]

1.2. Published in 2000: HEALTH OUTCOMES MANUSCRIPTS

1. Almond S, ÓDonnell O. Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone and haloperidol. *PharmacoEconomics* 2000; 17(4):383-389. Apr. [GHOR]
2. Edgell E, Andersen SW, Dulisse BK, Johnstone B, Revicki D, Breier A. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. *PharmacoEconomics* 2000; 6:567-579. Dec. [HGBG]
3. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. *International Clinical Psychopharmacology* 2000; 15(5):245-255. Sep. [HGAJ]
4. McCombs J, Luo M, Johnstone B, Shi L. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over two years. *Value in Health* 2000; 3(3):222-231.

ZY 2230 1863

5. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use patterns and the cost of treating schizophrenia. *Psychiatric Services* 2000; 51(4):525-527. Apr. **[Medicaid CA Cost of Schz Tx]**
6. McCombs JS, Stimmel, G, Johnstone BM, Nichols M. Antipsychotic drug use patterns and the cost of treating schizophrenia. *Psychiatric Services* 2000; 51(4):525-527. Apr. **[Medicaid CA Cost of Schz Tx]**
7. Noordsy DL, ÓKeefe C, Mueser KT, Xie H. Six-month outcomes for patients who switched to olanzapine treatment. *Psychiatric Services* 2001;52(4):501-507. Apr.

1.3. Published in 2000: BOOK CHAPTERS

Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, Tollefson GD. *Olanzapine (Zyprexa®)—A Novel Antipsychotic*. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2000.

1. Bymaster FP, Breier A, Tollefson GD, Herrera J, Tran PV. Preface: Olanzapine belongs to a new Multi-Acting-Receptor-Targeted-Antipsychotic (MARTA) class of antipsychotics. pp. ix-xi.
1. Seeman P, Kapur S. Chapter 1: Olanzapine binding to dopamine receptors in vitro and in vivo. pp. 3-24.
2. Fatemi SH, Meltzer HY. Chapter 2: Binding of olanzapine to serotonin receptor subtypes. pp. 25-30.
3. Calligaro DO. Chapter 3: Binding of olanzapine to other neuronal receptors. pp. 31-43.
4. Felder CC, Bymaster FP. Chapter 4: Functional interaction of olanzapine with neuronal receptor subtypes. pp. 44-53.
5. Ellenbroek BA. Chapter 5: The effects of olanzapine in animal models predictive of antipsychotic activity. pp. 57-68.
6. Casey DE. Chapter 6: Behavioral effects of olanzapine compared to typical and atypical antipsychotics in *Cebus* monkeys. pp. 67-75.
7. Moore NA. Chapter 7: Multiple behavioral actions of olanzapine: a compound with a 'rich' pharmacology. pp. 76-85.
8. Moore NA, Tye NC. Chapter 8: Effect of olanzapine on conflict behavior. pp. 86-92.
9. Geyer MA, Swerdlow NR. Chapter 9: Olanzapine in behavioral models of glutamatergic function. pp. 93-103.
10. Rasmussen K. Chapter 10: Electrophysiological effects of olanzapine on midbrain dopamine neurons. pp. 104-114.
11. Wang RY, Liang X, Jardemark KE, Aranov V. Chapter 11: Facilitation of NMDA transmission by olanzapine. pp. 114-131.
12. Perry KW, Wong DT. Chapter 12: Olanzapine and neurotransmitter release: microdialysis studies in rat brain. pp. 135-145.
13. Zhang W, Bymaster FP. Chapter 13: *In vivo* receptor neurochemical studies with olanzapine. pp. 146-159.
14. Nisenbaum LK, Fibiger HC. Chapter 14: Effects of olanzapine and other antipsychotic drugs on *c-fos* expression. pp. 160-174.
15. Nyberg S. Chapter 15: Imaging studies on receptor binding of olanzapine and reference antipsychotics in the human brain. pp. 175-180.
16. Dean B, Scarr E, Hussain T, Naylor L, Hayes W, Pavey G, Pralong D, Copolov D. Chapter 16: Effect of chronic olanzapine treatment on neuronal receptors. pp. 181-196.
17. Kinkead B, Binder EB, Nemeroff CB. Chapter 17: Olanzapine and neurotensin. pp. 197-213.
18. Potts BD. Chapter 18: Disposition and biotransformation of olanzapine in animals and humans. pp. 217-231.
19. Bergstrom RF, Callaghan JT, Cerimele BJ, Kurtz DL, Hatcher BL. Chapter 19: Population pharmacokinetics and plasma concentrations of olanzapine. pp. 232-252.
20. Callaghan JT, Bergstrom RF. Chapter 20: Olanzapine: drug interaction. pp. 253-264.
21. Tran PV, Sutton VK, Beasley CM Jr, Tollefson GD. Chapter 21: Efficacy of olanzapine: a review. pp. 267-279.
22. Beasley CM Jr, Grundy SL, Gannon KS, Berg PH. Chapter 22: Overview of the safety of olanzapine. pp. 280-299.

ZY 2230 1864

23. Sutton VK, Herrera JM, Sramek JJ, Tran PV, Zhang F, Creanga D, Cousins L, Taylor C, Wang J, Kurtz D, Dossenbach M. Chapter 23: Ethnicity and olanzapine. pp. 300–311.
24. Aobi A, Mulholland L. Chapter 24: Clinical experience of olanzapine in Japan. pp. 312–324.
25. Dickson RA. Chapter 25: Gender, prolactin and olanzapine. pp. 323–336.
26. Kennedy JS. Chapter 26: Olanzapine and the cholinergic system: an evolving scientific inquiry. pp. 335–342.
27. Revicki DA, Namjoshi MA, Edgell ET. Chapter 27: Health-related quality of life measurement in schizophrenia: a review of previous research and clinical trial results with olanzapine treatment. pp. 343–358.
28. Kinon BJ. Chapter 28: Antipsychotic drug noncompliance in the treatment of schizophrenia and the role of olanzapine. pp. 357–368.
29. Grainger D. Chapter 29: Pharmacoeconomics of olanzapine. pp. 369–385.
30. Purdon SE. Chapter 30: Models of cognition: olanzapine in relation to other second generation antipsychotics. pp. 379–400.
31. Stip E. Chapter 31: Olanzapine and cognition. pp. 401–415.
32. Street J, Kinon B, Stauffer V. Chapter 32: Olanzapine in dementia. pp. 416–426.
33. Tollefson GD. Chapter 33: Treatment of depression and anxiety symptoms comorbid with schizophrenia by olanzapine and other antipsychotics. pp. 427–451.
34. Brunner E, Tohen M. Chapter 34: Olanzapine in bipolar disorder. pp. 452–459.
35. Fung M, Corbin L, Brookfield W, Wu H-H, Hornbuckle K. Chapter 35: The effectiveness of olanzapine in internally and externally directed hostility and aggression. pp. 460–471.

2. Published in 1999

2.1. Published in 1999: MEDICAL MANUSCRIPTS

1. Beasley CM Jr, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. *British Journal of Psychiatry* 1999; 174:23–30. Jan. [E003, HGAD, HGAJ]
2. Beuzen JN, Taylor N, Wesnes K, Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. *Journal of Psychopharmacology* 1999; 13(2):152–158.
3. Breier A, Berg PH. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. *Biological Psychiatry* 1999; 46(3):361–364. 01-Aug. [Review]
4. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol with treatment-resistant schizophrenia. *Biological Psychiatry* 1999; 45(4):403–411. 15 Feb. [HGAJ]
5. Bymaster FP, Moore NA, Nakazawa T. Review of the preclinical pharmacology of olanzapine: a MARTA class antipsychotic. *Japanese Journal of Clinical Psychopharmacology* 1999; 2:885–911. [Review – Preclinical]
6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO. Antagonism by olanzapine of dopamine D₁, serotonin₂, muscarinic, histamine H₁ and alpha₁-adrenergic receptors in vitro. *Schizophrenia Research* 1999; 37(1):107–22. 04-May. [Preclinical]
7. Bymaster FP, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. *British Journal of Psychiatry* 1999; 174(suppl 37):36–40. [Review – Preclinical]
8. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM Jr. Olanzapine: pharmacokinetic and clinical trial profiles. *Clinical Pharmacokinetics* 1999; 37(3):177–193. Sep. [Pharmacokinetics]
9. Gutierrez M, Miro E, Chincilla A, Otero A, Sala JM, Lopez-Carrero C, Gómez JC. Comparacion entre olanzapina y risperidona en el tratamiento de la esquizofrenia y de otros trastornos psicoticos: resultados de un estudio aleatorizado y doble ciego

ZY 2230 1865

- [Comparison between olanzapine and risperidone in the treatment of schizophrenia and other psychotic disorders: results of a randomized and double-blind study]. *Psychiatria Biologica* 1999; 6:49-54. [HGBG]
10. Jakovljevic M, Dossenbach MRK, et al. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. *Psychiatria Danubina* 1999; 11(1-2):3-10. [HGCH]
 11. Lee H, Tarazi F, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. *Life Sciences* 1999; 64(18):1595-1602. [Preclinical]
 12. Moore NA. Olanzapine: preclinical pharmacology and recent findings. *British Journal of Psychiatry* 1999;174(suppl 37):41-44. [Review - Preclinical]
 13. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. *American Journal of Psychiatry* 1999; 156(1):79-87. Jan. [HGAJ]
 14. Timmerman W, Heijmen M, Westerink BHC, Bruggeman R, den Boer JA. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. *Psychopharmacology* 1999; 144(3):286-294. Jun. [Preclinical]
 15. Tohen M, Brunner E, Grundy S. Olanzapina: un nuevo antipsicótico [Olanzapine: a new antipsychotic]. *Acta Psiquiátrica y Psicológica de América Latina* 1999; 45(4). Dec. [E003, HGAD, HGAJ, HGAP]
 16. Tohen M, Grundy SL. Management of acute mania. *Journal of Clinical Psychiatry* 1999; 60(suppl 5):31-34. [Review]
 17. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. *American Journal of Psychiatry* 1999; 156(5):702-709. May. [HGEH]
 18. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind randomized comparison of olanzapine and risperidone. *Biological Psychiatry* 1999; 46(3):365-373. 01-Aug. [HGBG]
 19. Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ. A controlled, double-blind investigation of clozapine discontinuation syndrome and switching with conversion to either olanzapine or placebo. *Journal of Clinical Psychopharmacology* 1999; 19(5):435-444. Oct. [HGDY]
 20. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. *British Journal of Psychiatry* 1999; 174(suppl 37):30-35. [Review]
 21. Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? *Schizophrenia Research* 1999; 35(suppl):S13-S21. 01 Mar. [Review]
 22. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. *British Journal of Psychiatry* 1999; 174:15-22. Jan. [E003, HGAD, HGAJ]
 23. Tunis S, Johnstone B, Kinon B, Barber B, Browne R. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. *Value in Health* 2000; 3(3):232-242. [HGGD]

2.2. Published in 1999: HEALTH OUTCOMES MANUSCRIPTS

1. Cohen LJ. Benefits of olanzapine as first-line schizophrenia therapy [letter]. *American Journal of Health System Pharmacy* 1999; 56(15):1559-1560, 1563-1564.
2. Croghan TW, Johnstone BM, Buesching DP, Kessler RC. Information needs for medication coverage decisions in a state Medicaid program. *Medical Care*. 37(4 suppl Lilly):AS24-AS31, 1999 Apr 30. [Medicaid CA Cost of Schz Tx]
3. Edgell ET, Gregor KJ, Cockburn I. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine [letter]. *Clinical Therapeutics* 1999; 21(5):917-930. May. [Letter to the Editor regarding Procyslyn RM, Zerjav S. 1998;20(6):1203-1217.]

ZY 2230 1866

4. Edgell ET, Johnstone BM, Cohen LJ. Benefits of olanzapine as first-line schizophrenia therapy [letter]. *American Journal of Health-System Pharmacy* 1999; 56(15):1559–1560.
5. Foster RH, Goa KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. *Pharmacoeconomics* 1999; 15(6):611–640 Jun. **[Review]**
6. Gibson PJ, Koepsell TD, Diehr P, Hale CB. Increasing response rates for mailed surveys of Medicaid clients and other low income populations. *American Journal of Epidemiology* 1999; 149(11):1057–1062. 01 Jun.
7. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia—results from a randomised clinical trial. *Pharmacoeconomics* 1999; 15(5):469–480. May. **[HGAJ]**
8. Lehman AF, Tunis SL, Noordsy DL, Aquila R. The impact of schizophrenic patient functionality on service utilization and cost. *American Journal of Managed Care* 1999; 5(10 suppl):S538–S590.
9. Le Pen C, Lilliu H, Blachier C. Comparaison economique de l'olanzapine versus haloperidol dans le traitement de la schizophrénie en France [An economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France]. *Encéphale* 1999; 25(4):281–286. Jul–Aug. **[HGAJ]**
10. Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. *Journal of Clinical Psychiatry* 1999; 60(suppl 19):14–19.
11. Noordsy DL, Ó Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. *Journal of Clinical Psychiatry* 1999; 60(suppl 19):47–51. **[ITT]**
12. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: quality of life outcomes of a randomized clinical trial. *Quality of Life Research* 1999; 8:417–426. Aug. **[HGAJ]**
13. Salvador-Carulla L, Haro JM, Cabasés J, Madoz V, Sacristán JA, Vázquez-Barquero JL. Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST Group. *Acta Psychiatrica Scandinavica* 1999; 100(5):335–343. Nov.
14. Tunis SL. The impact of schizophrenic patient functionality on service utilization and cost. *American Journal of Managed Care* 1999; 5(1 suppl):S583–S590. **[HGFI]**
15. Tunis SL, Croghan TW, Heilman DK. Reliability, validity and application of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in schizophrenia patients treated with olanzapine versus haloperidol. *Medical Care* 1999; 37(7):678–691. Jul. **[HGAJ]**
16. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. *Journal of Clinical Psychiatry* 1999; 60(suppl 19):38–45. **[HGGD]**
17. Tunis SL, Noordsy DL, Mauskopf JA, Aquila R, Lehman AF. Evaluation of outcomes for atypical antipsychotic therapy and psychosocial rehabilitation in a community mental health center setting. *American Journal of Managed Care* 1999; 5(10 suppl):S591–S600.
18. Tunis SL, Noordsy DL, Mauskopf JA, Aquila R, Lehman AF. Effectiveness of combining atypical antipsychotic therapy and psychosocial rehabilitation in a CMHC setting. *Journal of Clinical Psychiatry* 1999; 60(suppl 19):52–53.
19. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. *Medical Care* 1999; 37(4):AS81–AS86. **[HGGD]**

ZY 2230 1867

2.3. Published in 1999: SUPPLEMENT CHAPTERS

British Journal of Psychiatry 1999; 174 (Supplement 37)

1. Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency model of schizophrenia. *British Journal of Psychiatry* 1999; 174(suppl 37):2-6.
2. Tandon R. Cholinergic aspects of schizophrenia. *British Journal of Psychiatry* 1999; 174(suppl 37):7-11.
3. Tamminga C. Glutamatergic aspects of schizophrenia. *British Journal of Psychiatry* 1999; 174(suppl 37):12-15.
4. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. *British Journal of Psychiatry* 1999; 174(suppl 37):16-18.
5. Marder SR. An approach to treatment resistance in schizophrenia. *British Journal of Psychiatry* 1999; 174(suppl 37):19-22.
6. Paul S. CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back. *British Journal of Psychiatry* 1999; 174(suppl 37):23-25.
7. Kane J. Olanzapine in the long-term treatment of schizophrenia. *British Journal of Psychiatry* 1999; 174(suppl 37):26-29.
8. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. *British Journal of Psychiatry* 1999; 174(suppl 37):30-35.
9. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. *British Journal of Psychiatry* 1999; 174(suppl 37):36-40.
10. Moore NA. Olanzapine: preclinical pharmacology and recent findings. *British Journal of Psychiatry* 1999; 174(suppl 37):41-44.

3. Published in 1998

3.1. Published in 1998: MEDICAL MANUSCRIPTS

1. Kinon BJ. The routine use of atypical antipsychotics agents: maintenance treatment. *Journal of Clinical Psychiatry* 1998; 59(suppl 19):18-22. **[Review]**
2. Lokshin P, Dorfman P, Shoshani D, et al. Olanzapine treatment after clozapine-induced agranulocytosis. *Human Psychopharmacology* 1998; 13:583-584. **[Case Report]**
3. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. *European Journal of Clinical Pharmacology* 1998; 54:639-643. Oct. **[Pharmacokinetics]**
4. Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT. Lack of an effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. *Pharmacotherapy* 1998; 18(6):1237-1248. Nov-Dec. **[Pharmacokinetics]**
5. Sheitman BB, Kinon BJ, Ridgway BA, Lieberman JA. Pharmacological treatments of schizophrenia. In: Nathan PE, Gorman JM (eds). *A Guide to Treatments That Work*. New York, NY: Oxford University Press; 1998; 167-189. **[Review]**
6. Tohen M, Gannon KS. Treatment-resistant bipolar disorder. *Psychiatric Annals* 1998; 28(11):629-632 **[Review]**
7. Tohen M, Grundy SL. The use of mood stabilizers for treating psychiatric disorders: acute mania. *Journal of Clinical Psychiatry* (Audiograph Series) 1998; 1(6). **[Review]**
8. Tohen M, Grundy S. Polydipsia, water intoxication, and hyponatremia. *PsychLine* 1998; 2(4):32-34. **[Review]**
9. Tollefson GD, Sanger TM, Beasley CM Jr, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. *Biological Psychiatry* 1998; 43(11):803-810. 01 Jun. **[HGAD]**
10. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. *Archives of General Psychiatry* 1998; 55(3):250-258. Mar. **[HGAJ]**

ZY 2230 1868

11. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. *British Journal of Psychiatry* 1998; 172:499-505. Jun. [E003, HGAD, HGAJ]

3.2. Published in 1998: HEALTH OUTCOMES MANUSCRIPTS

1. Glazer WM. Atypical antipsychotics and formulary decisions. *American Journal of Managed Care* 1998; 4(suppl):S8-S14. [HGAJ]
2. Glazer WM. Formulary decisions and health economics. *Journal of Clinical Psychiatry* 1998; 59(suppl 19):23-29. [HGAJ]
3. Haley JC, Russo PA, Johnstone BM, Vrown WH. Prospective, naturalistic outcomes measurement: the Schizophrenia Care and Assessment Program (SCAP). *Value in Health* 1998; 1:89. [SCAP]
4. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. *Neuropsychopharmacology* 1998; 18(1):41-49. Jan. [HGAD]
5. Haro JM, Salvador-Carulla L, Cabasés J, Madoz V, Vázquez-Barquero, and the PSICOST Group. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. *British Journal of Psychiatry* 1998; 173:334-340. Oct.
6. Li Z, Hutchins DS, Johnstone BM, Tunis SL, Coleman TR, Gevirtz F. Duration of continuous therapy between atypical and typical antipsychotics. *Value in Health* 1998; 1:80-81. [PCS]
7. Li Z, Hutchins DS, Johnstone BM, Tunis SL, Coleman TR, Gevirtz F. Month-to-month adherence with antipsychotic pharmacotherapy: a comparison between atypical and typical antipsychotics. *Value in Health* 1998; 1:81. [PCS]
8. Sacristan JA, Gomez JC, Martín J, Garcia-Bernardo E, Peralta V, Alavarez E, Gurpegui M, and the Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. *Clinical Drug Investigation* 1998; 15(1):29-35. [HGBK]

4. Published in 1997

4.1. Published in 1997: MEDICAL MANUSCRIPTS

1. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. *European Neuropsychopharmacology* 1997; 7(2):125-137. May. [E003]
2. Callaghan JT, Cerimele BJ, Kassahun KJ, Nyhart EH Jr, Hoyes-Beehler PJ, Kondraske GV. Olanzapine: interaction study with imipramine. *Journal of Clinical Pharmacology* 1997; 37(10):971-978. Oct. [Pharmacokinetics]
3. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. *Schizophrenia Research* 1997; 26(1):41-54. 25 Jul. [HGAD]
4. Dellva MA, Tran PV, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. *Psychiatric Services* 1997; 48(12):1571-1577. Dec.
5. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. *Neuropsychopharmacology* 1997; 17(4):205-229. Oct.
6. Martín J, Gómez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M, and the Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. *Journal of Clinical Psychiatry* 1997; 58(11):479-483. Nov. [HGBK]
7. Sacristan JA, Gómez JC, Salvador-Carulla L. Analisis coste-efectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en España [Cost-effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain].

ZY 2230 1869

Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1997; 25(4):225-234.

8. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. *American Journal of Psychiatry* 1997; 154(9):1248-1254. Sep. [HG AJ]
9. Tollefson GD, Beasley CM Jr, Tran PV, Street J, Krueger J, Tamura RN, Graffeo K, Thieme M. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. *American Journal of Psychiatry* 1997; 154(4):457-465. Apr. [HG AJ]
10. Tollefson GD, Sanger TM. Negative symptoms: a path-analytic approach to the double-blind, placebo- and haloperidol-controlled clinical trial experience with olanzapine. *American Journal of Psychiatry* 1997; 154(4):466-474. Apr.
11. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr., Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. *Journal of Clinical Psychiatry* 1997; 58(5):205-211. May. [HG AJ, HG AD, E003]
12. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr., Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *Journal of Clinical Psychopharmacology* 1997; 17(5):407-418. Oct. [HG BG]

4.2. Published in 1997: SUPPLEMENT CHAPTERS

Journal of Clinical Psychiatry 1997; 58 (Supplement 10)

1. Tamminga CA, Conley RR. The application of neuroimaging techniques to drug development. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):3-6.
2. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):7-12.
3. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):18-21.
4. Weinberger DR. The biological basis of schizophrenia: new directions. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):22-27.
5. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):28-36.
6. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):37-44.
7. Nemeroff CB. Dosing the antipsychotic medication olanzapine. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):45-49.
8. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):50-54. [HG AJ]
9. Casey DE. The relationship of pharmacology to side effects. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):55-62.
10. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medication. *Journal of Clinical Psychiatry* 1997; 58(suppl 10):63-72.

5. Published in 1996

5.1. Published in 1996: MEDICAL MANUSCRIPTS

1. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind fixed dose olanzapine trial. *Psychopharmacology* 1996; 124(1-2):159-167. Mar. [HG AP]
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, and the Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute

ZY 2230 1870

- phase results of the North American double-blind olanzapine trial.
Neuropsychopharmacology 1996; 14(2):111-123. Feb. [HGAD]
3. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. *Psychopharmacology (Berlin)* 1996; 124(1-2):2-34. Mar.

6. Published in 1995

6.1. Published in 1995: MEDICAL MANUSCRIPTS

1. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. *International Clinical Psychopharmacology* 1995; 10(4):239-244. Nov.

ZY 2230 1871